Health & Environmental Research Online (HERO)


Print Feedback Export to File
6833625 
Journal Article 
Pregnancy per- and polyfluoroalkyl substance concentrations and postpartum health in project viva: A prospective cohort 
Mitro, SD; Sagiv, SK; Fleisch, AF; Jaacks, LM; Williams, PL; Rifas-Shiman, SL; Calafat, AM; Hivert, MF; Oken, E; James-Todd, TM 
2020 
Yes 
Journal of Clinical Endocrinology and Metabolism
ISSN: 0021-972X
EISSN: 1945-7197 
ENDOCRINE SOC 
WASHINGTON 
105 
e3415–e3426 
English 
Context
Per- and polyfluoroalkyl substances (PFAS) are environmental chemicals linked to weight gain and type 2 diabetes.
Objective
We examined the extent to which PFAS plasma concentrations during pregnancy were associated with postpartum anthropometry and biomarkers.
Design, Patients, and Measures
We studied women recruited between 1999 and 2002 in the Project Viva prospective cohort with pregnancy plasma concentrations of PFAS, including perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and 2-(N-ethyl-perfluorooctane sulfonamide) acetic acid (EtFOSAA). Three-year postpartum anthropometry measurements were available from 786 to 801 women, blood pressure from 761 women, and blood biomarkers from 450 to 454 women. We used multivariable regression to evaluate the association of log2-transformed PFAS with postpartum anthropometry, blood pressure, and blood biomarkers (leptin, adiponectin, sex hormone binding globulin [SHBG], hemoglobin A1c, interleukin-6 [IL-6], C-reactive protein), adjusting for age, prepregnancy body mass index, marital status, race/ethnicity, education, income, smoking, parity, and breastfeeding history.
Results
Pregnancy concentrations of certain PFAS were associated with greater adiposity (eg, 0.4 cm [95% confidence interval [95%CI]: −0.1, 0.9] greater waist circumference per doubling in EtFOSAA; 0.2 cm [95%CI: −0.1, 0.5] greater mid-upper arm circumference per doubling in PFOA; 1.2 mm [95%CI: 0.1, 2.2] thicker sum of subscapular and triceps skinfolds per doubling in PFOS) and higher systolic blood pressure (eg, 1.2 mm Hg [95%CI: 0.3, 2.2] per doubling in PFOS) at 3 years postpartum. Higher EtFOSAA concentrations were also associated with 10.8% higher IL-6 (95%CI: 3.3, 18.9) and 6.1% lower SHBG (95%CI: 0.7, 11.2) per doubling.
Conclusions
Pregnancy concentrations of EtFOSAA, PFOS, and PFOA were associated with adverse postpartum cardiometabolic markers. 
PFAS; anthropometry; biomarkers; pregnancy; postpartum 
PFAS
• Expanded PFAS SEM (formerly PFAS 430)
     Litsearch Update: November 2021
          PubMed
          Web of Science
     Screened Studies
          Excluded
               Exclude (TIAB)
     Perfluorooctane
     Potassium perfluorooctanoate
     2-(N-Ethylperfluorooctanesulfonamido)acetic acid
• PFAS 150
     Literature Search Update December 2021
          PubMed
          WOS
     Missing 2021 searches
     Literature Search Update December 2020
          PubMed
     Literature Search August 2019
          PubMed
     Screened Studies
          Included
               Include (TIAB)
          Excluded
               Exclude (Full Text)
     N-Ethylperfluorooctanesulfonamide
     Perfluorooctane
• PFDA
     June 2022 Pelch Database
     Submitted to EPA
     Literature Searches (through April 2023 update and post-public comment/peer review)
          Other
               Published PFAS SEMs
          Title & Abstract Screening
               Tagged as Supplemental
                    Full Text Screening
                    Exposure assessment or qualitative exposure only
• PFHxS
     Database searches
          Pelch PFAS SEM
     Excluded
          TiAb
     Literature Search Update April 2023
          Included Met PECO
• PFNA
     June 2022 Pelch Database
• PFOA (335-67-1) and PFOS (1763-23-1)
     Literature Search Update (Apr 2019 - Sep 2020)
          PubMed
     LitSearch Update (Sept 2020 - Feb 2022)
          WOS
• PFOA and PFOS OW MCLG Approaches
     Cited in White Papers